Tags : Therapies

Pharma

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form

Shots: Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies The companies collaborated for the development of therapies to treat DM1 The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs Click here ­to­ read […]Read More

Biotech

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies

Shots: Insitro to receive $50M as up front, $20M as near-term operational milestones and is eligible to receive ~$2B+ as discovery, development, regulatory and commercial milestones along with royalties on sales of the therapies BMS will lead the clinical development, regulatory submissions, and commercialization activities. Insitro will apply its insitro Human (ISH) platform, to create […]Read More

Biotech

Sarepta Therapeutics Collaborates with University of Florida to Accelerate the

Shots: Sarepta to fund four research programs at the UF and will get an exclusive option to develop any new therapeutic compounds resulting from the funded research programs. The projects include exploratory research in novel gene therapy vectors, next-generation capsids, and gene editing technologies along with new therapeutic areas in degenerative genetic diseases The focus […]Read More

Biotech

Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel

Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will […]Read More

Regulatory

Pfizer with its Partner BioNTech Receives the US FDA’s Fast

Shots: The designation is based on preliminary data from P-I/II study assessing BNT162b1 including animal immunogenicity studies results that were released on Jul 01, 2020. Additionally, the early results of German trial evaluating BNT162b1 are expected in Jul 2020 The companies BNT162 mRNA-based vaccine program involves the evaluation of 4 investigational candidates developed to target […]Read More

Pharma

BMS Signs an Exclusive Option to License Agreement with Dragonfly

Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide IPR for multiple candidates developed using Dragonfly’s platform for multiple new targets The focus of the agreement is to expand the collaboration b/w the companies […]Read More

Pharma Regulatory

MHLW Approves Novartis’ Five New Therapies Expanding its Footprints in

Shots: The five therapies include Tabrecta (capmatinib) for advanced and recurrent unresectable NSCLC, Entresto (sacubitril valsartan sodium hydrate) for chronic HF, Mayzent (siponimod fumaric acid) for secondary PMS, Enerzair (glycopyrronium bromide, indacaterol acetate, mometasone furoate) and Atectura (indacaterol acetate, mometasone furoate) for different forms of asthma In 2020, Novartis has received seven approval in Japan […]Read More

Pharma

Merck Collaborates with Yumanity to Accelerate the Development of Two

Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs for the treatment of ALS and FTLD The collaboration integrates Yumanity’s drug discovery platform with Merck’s development and commercialization expertise in neuroscience    Yumanity and […]Read More

Pharma

Roche Signs an Agreement with Innovent to Develop Therapies for

Shots: Roche to receive upfront, development and commercial milestone payments plus royalties and retains option to license for each ex-China development and commercialization. Innovent to get non-exclusive access to certain technologies of Roche to discover and develop specific 2:1 T-cell bispecific Abs (TCB) and the universal CAR-T platform If Roche exercise the option, it will […]Read More

Pharma

Roche Signs a License Agreement with Arrakis Therapeutics for the

Shots: Arrakis to receive $190M up front in cash and is eligible to get several billion dollars in pre/clinical and commercial milestones along with royalties for products emerging from the collaboration Arrakis will be responsible for discovery and research activities of each target to a defined point while Roche will get right to exclusively pursue […]Read More